Effects of Polydeoxyribonucleotide in the Treatment of Pressure Ulcers

Abstract

This study aimed to examine the positive effects of polydeoxyribonucleotide (PDRN) on the wound-healing process in pressure ulcers. In this randomized controlled trial, the effects of PDRN were compared over time between an experimental group (n=11) and a control group (n=12). The former was administered the same dose of PDRN intramuscularly (1 ampule, 3 mL, 5.625 mg, for 5 days) for 2 weeks and perilesionally (1 ampule, 3 mL, 5.625 mg, twice a week) for 4 weeks. The primary endpoint for determining efficacy was wound healing in the pressure ulcers, which was reflected by the wound surface area determined using VISITRAK Digital (Smith & Nephew, Largo, FL). The secondary endpoint was the pressure ulcer scale for healing score, determined using pressure ulcer scale for healing (PUSH Tool 3.0 developed by the National Pressure Ulcer Advisory Panel). After the 4-week treatment period, PDRN therapy was found to significantly reduce the wound size and PUSH score, without adverse effect during the treatment. The findings indicate that PDRN can positively modify the wound healing process in pressure ulcers, and its use could improve the clinical outcomes of patients and lower the need for additional therapies or hospital stay.Graphical Abstract

Viscoelastic interactions between polydeoxyribonucleotide and ophthalmic excipients

“…Additionally, numerous clinical researches have demonstrated substantial would-healing properties of PDRN 2,[8][9][10] . Furthermore, PDRN is regarded as a safe and biocompatible drug when considering its constituents 1,3,11 .…”

The effect of polydeoxyribonucleotide prolotherapy on posterior tibial tendon dysfunction after ankle syndesmotic surgery

“…PDRN promotes healing in chronic wounds involving tissue damage by stimulating tissue reconstruction without any adverse effects. [6] PDRN is also known to act on the A2 purinergic receptor selectively to mediate neogenesis and cell growth. PDRN stimulates vascular endothelial growth factor, increases the rate of granulation tissue in fibroblast maturation and differentiation, and consequently accelerates the repair process.…”

“…PDRN stimulates vascular endothelial growth factor, increases the rate of granulation tissue in fibroblast maturation and differentiation, and consequently accelerates the repair process. [6,14] Moreover, PDRN lowers the expression of the inflammatory cytokines interleukin-6 and tumor necrosis factor—alpha, [6] a potential mechanism for its rapid antiinflammatory effect in PTT. Thus, PDRN was considered an effective therapeutic approach to improve the clinical outcome of PTTD.…”

“…Chronic and acute toxicity studies confirm that PDRN has no toxic effects on lungs, brain, liver, heart, and skeletal muscle on histologic and macroscopic analysis. [6] …”

“…[4] Polydeoxyribonucleotide (PDRN, Placentex integro; Mastelli srl, San Remo, Italy) promotes healing in chronic wounds involving tissue damage by stimulating tissue reconstruction without any adverse effects. [6] Prolotherapy is the injection of an irritant into a tendon insertion or ligament site with the main purpose of pain relief. [7] Herein, we reported a patient who received prolotherapy with PDRN for the maintenance and treatment of PTTD after ankle syndesmotic surgery.…”